Oppenheimer Analysts Give Alpine Immune Sciences (ALPN) a $13.00 Price Target

Share on StockTwits

Oppenheimer set a $13.00 price objective on Alpine Immune Sciences (NASDAQ:ALPN) in a report released on Tuesday morning. The brokerage currently has a buy rating on the biotechnology company’s stock. Oppenheimer also issued estimates for Alpine Immune Sciences’ Q1 2019 earnings at ($0.58) EPS, Q2 2019 earnings at ($0.57) EPS, Q3 2019 earnings at ($0.59) EPS, Q4 2019 earnings at ($0.61) EPS, FY2019 earnings at ($2.35) EPS, FY2020 earnings at ($2.28) EPS, FY2021 earnings at ($2.39) EPS, FY2022 earnings at ($2.45) EPS and FY2023 earnings at ($2.29) EPS.

A number of other research analysts have also issued reports on the company. ValuEngine upgraded Alpine Immune Sciences from a sell rating to a hold rating in a report on Tuesday, March 5th. reiterated a buy rating and issued a $13.00 target price on shares of Alpine Immune Sciences in a report on Tuesday, February 12th. Finally, Zacks Investment Research upgraded Alpine Immune Sciences from a hold rating to a buy rating and set a $7.00 target price for the company in a report on Thursday, January 24th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has an average rating of Buy and a consensus price target of $12.00.

Shares of NASDAQ ALPN opened at $6.82 on Tuesday. Alpine Immune Sciences has a twelve month low of $3.66 and a twelve month high of $10.57. The company has a quick ratio of 9.20, a current ratio of 6.59 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $97.12 million, a PE ratio of -2.59 and a beta of 2.13.

Alpine Immune Sciences (NASDAQ:ALPN) last issued its quarterly earnings data on Monday, March 18th. The biotechnology company reported ($0.80) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.80). Alpine Immune Sciences had a negative return on equity of 60.81% and a negative net margin of 1,602.19%. As a group, research analysts anticipate that Alpine Immune Sciences will post -2.79 EPS for the current year.

In other Alpine Immune Sciences news, insider Mitchell Gold purchased 190,875 shares of the firm’s stock in a transaction on Friday, January 18th. The stock was bought at an average cost of $5.37 per share, with a total value of $1,024,998.75. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Tiger Management L.L.C. sold 25,000 shares of Alpine Immune Sciences stock in a transaction dated Friday, February 8th. The stock was sold at an average price of $5.85, for a total value of $146,250.00. The disclosure for this sale can be found here. Company insiders own 69.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in ALPN. Hikari Power Ltd purchased a new stake in Alpine Immune Sciences during the 4th quarter worth about $453,000. Victory Capital Management Inc. lifted its holdings in Alpine Immune Sciences by 109.0% during the 4th quarter. Victory Capital Management Inc. now owns 136,072 shares of the biotechnology company’s stock worth $501,000 after buying an additional 70,980 shares during the last quarter. Vanguard Group Inc lifted its holdings in Alpine Immune Sciences by 5.2% during the 3rd quarter. Vanguard Group Inc now owns 227,834 shares of the biotechnology company’s stock worth $1,442,000 after buying an additional 11,200 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Alpine Immune Sciences by 5.2% during the 3rd quarter. Vanguard Group Inc. now owns 227,834 shares of the biotechnology company’s stock worth $1,442,000 after buying an additional 11,200 shares during the last quarter. 53.83% of the stock is owned by institutional investors.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.

Read More: Dividend

Analyst Recommendations for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Qiwi PLC  Expected to Post Earnings of $0.31 Per Share
Qiwi PLC Expected to Post Earnings of $0.31 Per Share
Solaris  Hits Market Capitalization of $1.14 Million
Solaris Hits Market Capitalization of $1.14 Million
$1.37 Billion in Sales Expected for Caci International Inc  This Quarter
$1.37 Billion in Sales Expected for Caci International Inc This Quarter
TokenStars Trading 26.8% Higher  This Week
TokenStars Trading 26.8% Higher This Week
Akoustis Technologies Inc  Expected to Post Earnings of -$0.25 Per Share
Akoustis Technologies Inc Expected to Post Earnings of -$0.25 Per Share
Selfkey  24-Hour Trading Volume Hits $967,433.00
Selfkey 24-Hour Trading Volume Hits $967,433.00


© 2006-2019 Ticker Report